Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov;17(11):e012991.
doi: 10.1161/CIRCEP.124.012991. Epub 2024 Oct 24.

Using Atrial Fibrillation Burden Trends and Machine Learning to Predict Near-Term Risk of Cardiovascular Hospitalization

Affiliations

Using Atrial Fibrillation Burden Trends and Machine Learning to Predict Near-Term Risk of Cardiovascular Hospitalization

James Peacock et al. Circ Arrhythm Electrophysiol. 2024 Nov.

Abstract

Background: Atrial fibrillation is associated with an increased risk of cardiovascular hospitalization (CVH), which may be triggered by changes in daily burden. Machine learning of dynamic trends in atrial fibrillation burden, as measured by insertable cardiac monitors (ICMs), may be useful in predicting near-term CVH.

Methods: Using Optum's deidentified Clinformatics Data Mart Database (2007-2019), linked with the Medtronic CareLink ICM database, we identified patients with >1 days of ICM-detected atrial fibrillation. ICM-detected diagnostic parameters were transformed into simple moving averages over different periods for daily follow-up. A diagnostic trend was defined as the comparison of 2 simple moving averages of different periods for each diagnostic parameter. CVH was defined as any hospital, emergency department, or ambulatory surgical center encounter with a cardiovascular diagnosis-related group or diagnosis code. Machine learning was used to determine which diagnostic trends could best predict patient risk 5 days before CVH.

Results: A total of 2616 patients with ICMs met the inclusion criteria (71±11 years; 55% male). Among them, 1998 (76%) had a planned or unplanned CVH over 605 363 days. Machine learning revealed distinct groups: (A) sinus rhythm (reference), (B) below-average burden, (C) above-average burden, and (D) above-average burden with decreasing patient activity. The relative risk was increased in all groups versus the reference (B, 4.49 [95% CI, 3.74-5.40]; C, 8.41 [95% CI, 7.00-10.11]; D, 11.15 [95% CI, 9.10-13.65]), including a 21% increase in CVH detection over prespecified burden thresholds of duration (≥1 hour) and quantity (≥5%). The area under the receiver operating characteristic curve increased from 0.55 when using hourly burden amounts to 0.66 when using burden trends and decreasing patient activity (P<0.001), a 20% increase in predictive power.

Conclusions: Trends in atrial fibrillation were strongly associated with near-term CVH, especially above-average burden coupled with low patient activity. This approach could provide actionable information to guide treatment and reduce CVH.

Keywords: atrial fibrillation; data warehousing; hospitals; humans; risk.

PubMed Disclaimer

Conflict of interest statement

Dr Peacock serves as a consultant to Medtronic and Biotronik. E.J. Stanelle, Dr Johnson, and R. Kanwar are employed by Medtronic. D. Soderlund was formerly employed by Medtronic. Dr Hylek serves as a consultant for Bayer, Bristol Myers Squibb, Ionis, Janssen, and Pfizer, receives research grants from Abbott, Anthos Therapeutics, and Medtronic, and receives honoraria from Boehringer Ingelheim. Dr Lakkireddy serves as a consultant to Medtronic, Boston Scientific, Abbott, Atricure, AltaThera, Acutus, and AliveCor. Dr Mittal serves as a consultant to Abbott, Boston Scientific, and Medtronic. Dr Passman is supported by UG3HL165065 from NHLBI 18SFRN34250013 from the American Heart Association (AHA), receives a grant for clinical research from Abbott, serves as a consultant to Medtronic, Janssen Pharmaceuticals, and Abbott, and receives royalties from UpToDate. Dr Russo serves as a consultant for Abbott, Atricure, Bayer, Biosense Webster, Boston Scientific, Medtronic, and PaceMate receives grants for clinical research from Boston Scientific, Kestra, Medilynx, and Medtronic and receives honoraria from Biotronik, Bristol Myers Squibb, Pfizer, Medtronic, and Sanofi. Dr Piccini is supported by R01AG074185 from the National Institute on Aging receives grants for clinical research from Abbott, AHA, the Association for the Advancement of Medical Instrumentation, Bayer, Boston Scientific, iRhythm, and Philips serves as a consultant to Abbott, AbbVie, Ablacon, AltaThera, ARCA Biopharma, Biotronik, Boston Scientific, Bristol Myers Squibb, LivaNova, Medtronic, Milestone, Electrophysiology Frontiers, Pfizer, Sanofi, Philips, and UptoDate. The other author report no conflicts.

Figures

Figure 1.
Figure 1.
Definition of the index date. CE indicates continuous enrollment.
Figure 2.
Figure 2.
Mapping atrial fibrillation (AF) burden trends to a single patient example. This figure presents AF burden values as bars and AF burden moving averages as lines for each follow-up day between the day after device implantation and the day before cardiovascular hospitalization. First AF detection and moving average cross-over events trigger different windows of risk. Trend A represents a window of sinus rhythm before the patient’s first device-detected AF event (baseline risk). Trend B is triggered when the 21-day moving average of AF burden crosses below its historical average (below average risk). Trend C is triggered when the 21-day moving average of AF burden crosses above its historical average (above average risk). Moving averages are adjusted downward by 5 minutes for display purposes. AT indicates atrial tachycardia; CMA, cumulative moving average; and SMA, simple moving average.
Figure 3.
Figure 3.
Venn diagram of cardiovascular hospitalization (CVH) events by atrial fibrillation (AF) burden criteria. This Venn diagram shows the number of CVH events (%) and relative risk for the intersection of AF burden duration (≥1 hour), quantity (≥5%), and Trend D (increasing burden with decreasing patient activity) sets. Trend D captures 137 mutually exclusive CVH events, yielding a 21% (137/644) increase in detection over clinical criteria alone. The size of the Venn diagram circles and their overlay are kept constant for ease of presentation and thus do not represent the relative contribution of each set. RR indicates relative risk.
Figure 4.
Figure 4.
Distribution of daily atrial tachycardia (AT)/atrial fibrillation (AF) amount by AF burden criteria. Using validation data, this plot visualizes the differences in daily AT/AF amount by AF burden threshold. Follow-up days are counted when the criteria or trend is met for the respective AF burden threshold and presented as a percent of total follow-ups. Of these days, follow-up days are further counted only for patients with persistent AF.

References

    1. Chen LY, Chung MK, Allen LA, Ezekowitz M, Furie KL, McCabe P, Noseworthy PA, Perez MV, Turakhia MP; American Heart Association Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; Council on Quality of Care and Outcomes Research; and Stroke Council. Atrial fibrillation burden: moving beyond atrial fibrillation as a binary entity: a scientific statement from the American Heart Association. Circulation. 2018;137:e623–e644. doi: 10.1161/CIR.0000000000000568 - PMC - PubMed
    1. Steinberg BA, Piccini JP. When low-risk atrial fibrillation is not so low risk: beast of burden. JAMA Cardiol. 2018;3:558–560. doi: 10.1001/jamacardio.2018.1205 - PubMed
    1. Chew DS, Li Z, Steinberg BA, O’Brien EC, Pritchard J, Bunch TJ, Mark DB, Patel MR, Nabutovsky Y, Greiner MA, et al. . Arrhythmic burden and the risk of cardiovascular outcomes in patients with paroxysmal atrial fibrillation and cardiac implanted electronic devices. Circ Arrhythm Electrophysiol. 2022;15:e010304. doi: 10.1161/CIRCEP.121.010304 - PubMed
    1. Steinberg BA, Hellkamp AS, Lokhnygina Y, Patel MR, Breithardt G, Hankey GJ, Becker RC, Singer DE, Halperin JL, Hacke W, et al. ; on behalf of the ROCKET-AF Steering Committee and Investigators. Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF trial. Eur Heart J. 2015;36:288–296. doi: 10.1093/eurheartj/ehu359 - PMC - PubMed
    1. Piccini JP, Passman R, Turakhia M, Connolly AT, Nabutovsky Y, Varma N. Atrial fibrillation burden, progression, and the risk of death: a case-crossover analysis in patients with cardiac implantable electronic devices. Europace. 2019;21:404–413. doi: 10.1093/europace/euy222 - PubMed